Pfizer Inc. (NYSE:PFE) Shares Purchased by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 224,651 shares of the biopharmaceutical company’s stock after buying an additional 5,924 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Pfizer were worth $6,465,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Moneta Group Investment Advisors LLC lifted its holdings in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley lifted its holdings in Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after buying an additional 348,628 shares in the last quarter. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after purchasing an additional 5,185,453 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.29 during midday trading on Wednesday, hitting $25.41. The company had a trading volume of 43,790,104 shares, compared to its average volume of 42,573,164. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a twelve month low of $25.26 and a twelve month high of $41.33. The business has a 50-day simple moving average of $27.23 and a two-hundred day simple moving average of $28.79. The firm has a market capitalization of $143.86 billion, a price-to-earnings ratio of 71.36, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the business earned $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.